Epstein-barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6656-6667

  Lan, Yu Yan ^a,b   Hsiao, Jenn Ren ^b   Chang, Kung Chao ^b   Chang, Jeffrey Shu Ming ^a   Chen, Chaio Wei ^a   Lai, Hsiao Ching ^a,b   Wu, Shih Yi ^a   Yeh, Tzu Hao ^a,b   Chang, Fang Hsin ^a,b   Lin, Wei Hung ^a,b   Su, Ih Jen ^a   Chang, Yao ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS LATENT MEMBRANE PROTEIN 2A; GELATINASE B; LATENT MEMBRANE PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION REGULATION; HELA CELL; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR BIOPSY; UPREGULATION;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 84864007453     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00174-12     Document Type: Article

References (78)

1. Adiseshaiah P, Lindner DJ, Kalvakolanu DV, Reddy SP. 2007. FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. Cancer Res. 67:6204-6211.
2. Allen MD, Young LS, Dawson CW. 2005. The Epstein-Barr virusencoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J. Virol. 79:1789 -1802.
3. Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I, Piechaczyk M. 2007. Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol. Cell. Biol. 27:3936 -3950.
4. Belguise K, Kersual N, Galtier F, Chalbos D. 2005. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24:1434 -1444.
5. Bergers G, et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:737-744.
6. Bonfil RD, et al. 2006. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int. J. Cancer 118:2721-2726.
7. Brooks L, Yao QY, Rickinson AB, Young LS. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:2689 -2697.
8. Bultema R, Longnecker R, Swanson-Mungerson M. 2009. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 28: 1471-1476.
9. Busson P, et al. 1992. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J. Virol. 66:3257-3262.
10. Casalino L, et al. 2007. Fra-1 promotes growth and survival in RAStransformed thyroid cells by controlling cyclin A transcription. EMBO J. 26:1878 -1890.
11. Casalino L, De Cesare D, Verde P. 2003. Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol. Cell. Biol. 23:4401- 4415.
12. Charalambous CT, Hannigan A, Tsimbouri P, McPhee GM, Wilson JB. 2007. Latent membrane protein 1-induced EGFR signalling is negatively regulated by TGFα prior to neoplasia. Carcinogenesis 28:1839 -1848.
13. Chen SY, Lu J, Shih YC, Tsai CH. 2002. Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J. Virol. 76:9556 -9561.
14. Chung TW, Lee YC, Kim CH. 2004. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 18:1123- 1125.
15. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2:161-174.
16. Fahraeus R, et al. 1988. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer 42:329 -338.
17. Fotheringham JA, Mazzucca S, Raab-Traub N. 2010. Epstein-Barr virus latent membrane protein-2A-induced ΔNp63α expression is associated with impaired epithelial-cell differentiation. Oncogene 29:4287- 4296.
18. Fruehling S, Longnecker R. 1997. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235:241-251.
19. Fruehling S, Swart R, Dolwick KM, Kremmer E, Longnecker R. 1998. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J. Virol. 72:7796 -7806.
20. Fukuda M, Longnecker R. 2004. Latent membrane protein 2A inhibits transforming growth factor-β1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J. Virol. 78:1697-1705.
21. Fukuda M, Longnecker R. 2007. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J. Virol. 81:9299 -9306.
22. Heussinger N, et al. 2004. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J. Pathol. 203:696-699.
23. Hino R, et al. 2008. Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res. 68:1427-1435.
24. Hino R, et al. 2009. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 69:2766 -2774.
25. Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M. 2000. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 89:715-723.
26. Hsiao JR, et al. 2009. Endoplasmic reticulum stress triggers XBP-1-mediated up-regulation of an EBV oncoprotein in nasopharyngeal carcinoma. Cancer Res. 69:4461- 4467.
27. Hsu M, et al. 2008. Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J. Virol. 82:3679 -3688.
28. Hua J, Muschel RJ. 1996. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56:5279 -5284.
29. Ikeda M, Ikeda A, Longnecker R. 2001. PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2Aassociated proteins. J. Virol. 75:5711-5718.
30. Kessenbrock K, Plaks V, Werb Z. 2010. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52- 67.
31. Kong QL, et al. 2010. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog. 6:e1000940.
32. Lee AW, et al. 1992. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 23:261-270.
33. Lin CC, et al. 2009. IL-1β promotes A549 cell migration via MAPKs/ AP-1- and NF-κB-dependent matrix metalloproteinase-9 expression. Cell Signal. 21:1652-1662.
34. Lin LF, et al. 2010. ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res. 70:192-201.
35. Liu Z, et al. 2010. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 10:270. doi: 10.1186/1471-2407-10-270.
36. Loesch M, et al. 2010. p38γ MAPK cooperates with c-Jun in transactivating matrix metalloproteinase 9. J. Biol. Chem. 285:15149 -15158.
37. Longnecker R, et al. 2000. WW- and SH3-domain interactions with Epstein-Barr virus LMP2A. Exp. Cell Res. 257:332-340.
38. Lu J, et al. 2006. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J. Biol. Chem. 281:8806-8814.
39. Manes S, et al. 1999. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem. 274:6935- 6945.
40. Mann B, et al. 1999. Target genes of β-catenin-T cell-factor/lymphoidenhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. U. S. A. 96:1603-1608.
41. Morrison JA, Klingelhutz AJ, Raab-Traub N. 2003. Epstein-Barr virus latent membrane protein 2A activates β-catenin signaling in epithelial cells. J. Virol. 77:12276 -12284.
42. Morrison JA, Raab-Traub N. 2005. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of β-catenin signaling. J. Virol. 79:2375-2382.
43. Muhlen S, Behren A, Iftner T, Simon C. 2010. Influence of HPV16 E2 and its localisation on the expression of matrix metalloproteinase-9. Int. J. Oncol. 37:337-345.
44. Pang MF, Lin KW, Peh SC. 2009. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer. Cell. Mol. Biol. Lett. 14:222-247.
45. Panousis CG, Rowe DT. 1997. Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase. J. Virol. 71:4752- 4760.
46. Pegtel DM, et al. 2005. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J. Virol. 79:15430 -15442.
47. Portis T, Dyck P, Longnecker R. 2003. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102:4166-4178.
48. Portis T, Longnecker R. 2004. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/ Akt pathway. Oncogene 23:8619-8628.
49. Preacher KJ, Hayes AF. 2004. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav. Res. Methods Instrum. Comput. 36:717-731.
50. Preacher KJ, Hayes AF. 2008. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav. Res. Methods 40:879-891.
51. Raab-Traub N. 2002. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12:431- 441.
52. Rickinson AB, Kieff E. 2007. Epstein-Barr virus, p 2655-2700. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
53. Sato H, Kita M, Seiki M. 1993. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J. Biol. Chem. 268:23460 -23468.
54. Sayan AE, et al. 2012. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene 31:1493-1503.
55. Scholle F, Bendt KM, Raab-Traub N. 2000. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 74:10681-10689.
56. Sheu BC, et al. 2001. A novel role of metalloproteinase in cancermediated immunosuppression. Cancer Res. 61:237-242.
57. Shin SY, Kim JH, Baker A, Lim Y, Lee YH. 2010. Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor α. Mol. Cancer Res. 8:507-519.
58. Shrout PE, Bolger N. 2002. Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychol. Methods 7:422- 445.
59. Sobel ME. 1982. Asymptotic confidence intervals for indirect effects in structural equation models, p 290-312. In Leinhardt S (ed), Sociological methodology 1982. American Sociological Association, Washington, DC.
60. Song Y, et al. 2008. Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. Mol. Immunol. 45:137-143.
61. Spano JP, et al. 2003. Nasopharyngeal carcinomas: an update. Eur. J. Cancer 39:2121-2135.
62. Sternlicht MD, Werb Z. 2001. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17:463-516.
63. Stewart S, et al. 2004. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-κB transcription factor pathway. Proc. Natl. Acad. Sci. U. S. A. 101:15730 -15735.
64. Swart R, Ruf IK, Sample J, Longnecker R. 2000. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase/Akt pathway. J. Virol. 74:10838 -10845.
65. Terasawa K, Okazaki K, Nishida E. 2003. Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Genes Cells 8:263-273.
66. Tiwari G, Sakaue H, Pollack JR, Roth RA. 2003. Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Aktinducible gene. Mol. Cancer Res. 1:475- 484.
67. Ueno S, et al. 2011. Asialoglycoprotein receptor promotes cancer metastasis by activating the EGFR-ERK pathway. Cancer Res. 71:6419-6427.
68. Usui A, et al. 25 October 2011. The molecular role of Fra-1 and its prognostic significance in human esophageal squamous cell carcinoma. Cancer [Epub ahead of print.] doi:10.1002/cncr.26652.
69. Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB. 2007. Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle 6:2633-2639.
70. Wang L, et al. 2004. The Kaposi's sarcoma-associated herpesvirus (KSHV/ HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res. 64:2774-2781.
71. Winberg G, et al. 2000. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol. Cell. Biol. 20:8526-8535.
72. Yen JH, Kocieda VP, Jing H, Ganea D. 2011. Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation. J. Biol. Chem. 286:38913-38923.
73. Yoshizaki T, Sato H, Furukawa M, Pagano JS. 1998. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. U. S. A. 95:3621-3626.
74. Young LS, et al. 1988. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 69:1051-1065.
75. Young MR, Colburn NH. 2006. Fra-1 a target for cancer prevention or intervention. Gene 379:1-11.
76. Young MR, et al. 2002. Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol. Cell. Biol. 22:587-598.
77. Yu Q, Stamenkovic I. 2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14:163-176.
78. Zhang L, et al. 2010. Fos-related activator-1 is overexpressed in oral squamous cell carcinoma and associated with tumor lymph node metastasis. J. Oral Pathol. Med. 39:470-476.